Cited by 20Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsClinical Laboratory Practices and Quality Control

Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples

Open access
Moore, Gary W., Maloney, James C., de Jager, Naomi, Dunsmore, Clare L., Gorman, Dervilla K., Polgrean, Richard F., Bertolaccini, Maria L.·2017·Research and Practice in Thrombosis and Haemostasis

Abstract

BACKGROUND: Gold standard lupus anticoagulant (LA) assays and reference plasmas do not exist and detection is based on inference in a medley of coagulation assays, creating potential for interpretive discrepancies when applying different algorithms. OBJECTIVES: To investigate discrepancies from applying different algorithms to a common data set. METHODS: Diagnostic data on 311 non-anticoagulated patients LA-positive by dilute Russell's viper venom time (dRVVT) and/or dilute activated partial thromboplastin time (dAPTT) assays were employed to compare algorithms. Routine testing applied interpretive criteria from guidelines endorsing classification as LA-positive despite negative mixing tests, after exclusion of other clotting abnormalities. Integrated testing without mixing tests, and the classical algorithm where negative mixing tests preclude confirm tests, were then retrospectively applied to those data. RESULTS: Initial testing showed 92/311 (29.6%) were LA-positive by dRVVT only, 156/311 (50.1%) by dAPTT only, and 63/311 (20.3%) by both assays. All dAPTT-positive plasmas remained positive with integrated testing but eight dRVVT-positives became negative. Other data suggested they were false-negatives. The classical algorithm altered 52/155 (33.5%) dRVVT and 111/219 (50.7%) dAPTT interpretations to LA-negative because of normal mixing tests, most of which were apparently weak LA in undiluted plasma. CONCLUSIONS: The classical algorithm improves diagnostic specificity and confidence but risks missing some genuine LA due to false-negative mixing tests. Integrated testing can be diagnostically accurate and logistically efficient but oversimplifies complex cases. Performing mix and confirm in response to an elevated screen with their interpretation based on clinical data, coagulation screens and the LA-assay design offers a potentially valuable option.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/rth2.12006

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • False-negative mixing tests can arise from reagent sensitivity and specificity to LA; some LAs that are positive in screening tests with both aPTT and dRVVT show positivity in the mixing test for one test but not the other.

    “False-negatives mixing tests can also arise for reasons other than dilution, such as reagents’ sensitivity and specificity to LA: some LAs, undoubtedly positive in screening tests with both aPTT and dRVVT, show positivity in the mixing for one test but not for the other [105,106].”

    From Lupus Anticoagulant Detection under the Magnifying Glass (2023) · cites this paper as [106]

    The Results and Discussion (page unavailable) report different false-negative mixing-test rates for dRVVT and dAPTT and identify reagent composition as a possible contributor to mixing-test results beyond antibody potency. The paper does not establish that samples positive on both screening tests were mixing-test positive on one assay but negative on the other, or that reagent sensitivity and specificity caused that particular pattern. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • There is currently no established gold standard assay or reference plasma for LA detection.

    “As a result, there are currently no established gold standard assays or reference plasmas for LA detection [[6], [7], [8], [9], [10]].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 25

  1. [1]Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295– 306. 16420554
  2. [3]Pengo V, Tripodi A, Reber G, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737– 40. 19624461
  3. [4]Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47– 58. 22313321
  4. [6]Devreese KMJ. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants? J Thromb Haemost 2010; 8: 1120– 2. 20149080
  5. [7]Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012; 38: 385– 9. 22618530
  6. [8]Reber G, Meijer P. In ECAT veritas? Lupus. 2012; 21: 722– 4. 22635212
  7. [9]Hong SK, Hwang SM, Kim JE, Kim HK. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems. Blood Coagul Fibrinolysis 2012; 23: 739– 44. 22964767
  8. [10]Pennings MT, De Groot PG, Meijers JC, Huisman A, Derksen RH, Urbanus RT. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma? Thromb Haemost 2014; 112: 736– 42. 25008787
  9. [11]Aboud M, Morel‐Kopp MC, Ward C, Coyle L. False‐negative or false‐positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant. J Thromb Haemost 2010; 8: 2070– 3. 20553379
  10. [12]Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8: 2828– 31. 21029364
  11. [14]Devreese KM. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants. Thromb Res 2007; 119: 369– 76. 16704874
  12. [16]Moore GW, Brown KL, Bromidge ES, Drew AJ, Ledford‐Kraemer MR. Lupus anticoagulant detection: out of control? Int J Lab Haematol. 2013; 35: 128– 36. 22978522
  13. [17]McGlasson DL, Fritsma GA. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits. Semin Thromb Hemost 2013; 39: 315– 9. 23468380
  14. [18]Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704– 15. 10929019
  15. [19]Lawrie AS, Mackie IJ, Purdy G, Machin SJ. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo‐optical and mechanical coagulometers. Thromb Haemost 1999; 81: 758– 62. 10365750
  16. [21]Depreter B, Devreese KM. Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation. Clin Chem Lab Med 2016; 54: 1511– 6. 26894579
  17. [22]CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline—Third Edition. CLSI document C28‐A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
  18. [23]Gerbutavicius R, Fareed J, Messmore HL Jr, et al. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. Clin Appl Thromb Hemost 2002; 8: 115– 24. 12121051
  19. [24]Tripodi A, Chantarangkul V, Cini M, et al. Variability of cut‐off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study. J Thromb Haemost 2017; 15: 1180– 90. 28316135
  20. [25]Fritsma GA, Dembitzer FR, Randhawa A, et al. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. Am J Clin Pathol 2012; 137: 904– 8. 22586049
  21. [26]Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by North American clinical laboratories. Am J Clin Pathol 2010; 134: 764– 73. 20959659
  22. [27]Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost 2011; 9: 2117– 9. 21794074
  23. [28]Moore GW, Sangle SR, Archer RA, Maloney JC, Rahman A, D'Cruz DP. Complete prekallikrein deficiency masquerading as a lupus anticoagulant. Thromb Res 2014; 133: 301– 2. 24315318
  24. [29]Machin SJ, Giddings JC, Greaves M, et al. Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1991; 44: 885– 9. 1752976 PMC496623
  25. [30]Jacobsen EM, Wisløff F. False negative screening tests for lupus anticoagulants—an unrecognized problem? Thromb Res 1996; 82: 445– 51. 8771705

Cited by

Sorted by citations

Authors
Moore, G. W., Maloney, J. C., de Jager, N., Dunsmore, C. L., Gorman, D. K., Polgrean, R. F., & Bertolaccini, M. L.
Affiliations
St Thomas' Hospital (GB)
Corresponding author
Moore, Gary W.
Venue
Research and Practice in Thrombosis and Haemostasis
Publisher
Elsevier BV
Published
2017-07
Volume
1
Issue
1
Pages
62-68
ISSN
2475-0379 (ISSN-L)
OpenAlex
W2669292274
Cited by
20
References
5
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 2 · 2019: 2 · 2017: 1
FWCI
0.72
Type
journal article
Language
en
Open access
Locations
  • Research and Practice in Thrombosis and Haemostasis (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
Keywords
lupus anticoagulant, diagnostic algorithm, dilute Russell's viper venom time, mixing test, confirmatory testing, false-negative results, diagnostic specificity, anticoagulant screening

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review